Clinical trials
Observational Dyslipidemias trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
13 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2003 | 1 |
| 2008 | 2 |
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 7 |
| Recruiting | 3 |
| Unknown status | 2 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 2 |
| Hospices Civils de Lyon | 2 |
| University Hospital, Montpellier | 2 |
| Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 1 |
| Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi) | 1 |
| Franck Boccara | 1 |
| Institut National de la Santé Et de la Recherche Médicale, France | 1 |
| Newcastle University | 1 |
| Novartis Pharmaceuticals | 1 |
| Saint Antoine University Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Dyslipidemias | 13 |
| Cardiovascular Diseases | 5 |
| Atherosclerosis | 4 |
| Hypercholesterolemia | 3 |
| Diabetes Mellitus | 2 |
| Hypertension | 2 |
| Lipid Metabolism Disorders | 2 |
| Arterial Occlusive Diseases | 1 |
| Arteriosclerosis | 1 |
| Carcinoma, Hepatocellular | 1 |
Trials
Showing 1 to 13 of 13. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.